(2021) 6:e005799
to commercialize copper peptide products
Some preclinical studies show that BPC-157 can reduce inflammation and protect tissues in animal models, and those effects involve modulation of inflammatory responses and signaling pathways that overlap with immune activity
Dec 18, 2025, 08:00 ET CagriSema 2.4 mg/2.4 mg is an investigational fixed-dose injectable medicine that combines the novel amylin analogue, cagrilintide, with semaglutide to target complementary obesity-related pathways 1,2 In the REDEFINE 1 phase 3 trial, adults with obesity, or overweight with at least one obesity-related complication, taking CagriSema lost an average of 23% body weight when evaluating the treatment effect if all patients stayed on treatment *2 Novo Nordisk continues to build on its 100-year-plus legacy of science and innovation, with potential new treatments in obesity PLAINSBORO, N.J
Higashi T et al
Most peptides can be stored for more than half a year using this storage method, and peptides with less stability can be stored for more than 3 months